SEC Form 4 · accession 0002043558-26-000002
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jayson Rieger
Officer — CEO and President · Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001660334
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $8.21 | Jun 5, 2026 | A | 512,269 | A | — | Dec 23, 2035 | Common Stock | 512,269 | 512,269 | D |
Explanation of responses
- F1The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.
- F250% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.